Oxford Nanopore Technologies plc

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Real-time Estimate Cboe Europe Other stock markets 03:16:14 2024-05-29 am EDT			5-day change	1st Jan Change
112 ^GBX	+1.96%		+1.66%	-46.88%

May. 23	Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline	CI
May. 03	Jefferies cuts AJ Bell; Deutsche likes ConvaTec	AN

Oxford Nanopore Technologies Limited Appoint Wendy Becker as Senior Independent Director, Effective 21 January 2022

January 24, 2022 at 10:00 am EST

Oxford Nanopore Technologies Limited announces that Wendy Becker has been appointed as Senior Independent Director for the Company with effect from 21 January 2022.

Latest news about Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline	May. 23	CI
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	May. 03	AN
Jefferies raises B&M to 'hold'	Apr. 22	AN
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	Apr. 02	AN
Kepler Cheuvreux likes Diageo; BofA lifts Man	Mar. 14	AN
IP Group net asset value declines amid supply chain issues, inflation	Mar. 13	AN
Transcript : Oxford Nanopore Technologies plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	Mar. 12
Oxford Nanopore Technologies Launches PromethION 2 Integrated into Open Early Access	Mar. 07	CI
Good signals from central banks	Mar. 07
Oxford Nanopore Technologies top team buys shares	Mar. 07	AN
ANALYST RECOMMENDATIONS : AMD, Micron Technology, Snowflake, Zoom, Okta...	Mar. 07
ITV, LondonMetric, Man, Domino's get upgrades	Mar. 07	AN
What’s happening to the US economy?	Mar. 06
Oxford Nanopore confident in future opportunities despite weak 2023	Mar. 06	AN
ANALYST RECOMMENDATIONS : Crowdstrike, Target, Antofagasta, Direct Line Insurance, Premier Foods...	Mar. 06
Shares rise in London ahead of budget	Mar. 06
Oxford Nanopore Technologies' FY23 Loss Widens; Revenue Falls	Mar. 06	MT
Transcript : Oxford Nanopore Technologies plc, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
ConvaTec profit doubles; DS smith trades in line	Mar. 06	AN
Earnings Flash (ONT.L) OXFORD NANOPORE TECHNOLOGIES Reports FY23 Revenue GBP169.7M	Mar. 06	MT
Earnings Flash (ONT.L) OXFORD NANOPORE TECHNOLOGIES Reports FY23 Loss GBX-19.00	Mar. 06	MT
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2024	Mar. 06	CI
Oxford Nanopore Technologies plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
EXECUTIVE CHANGES: Metro Bank names new CFO; Corre exec leaves	Feb. 29	AN
Oxford Nanopore Technologies plc Announces Directorate Change	Feb. 29	CI

Chart Oxford Nanopore Technologies plc

Duration

Period

More charts

Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Companyâs segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-10 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oxford Nanopore Technologies plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.098 GBP

Average target price

1.98 GBP

Spread / Average Target

+80.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
OXFORD NANOPORE TECHNOLOGIES PLC	-46.88%	1.21B
THERMO FISHER SCIENTIFIC	+7.87%	219B
DANAHER CORPORATION	+11.83%	192B
INTUITIVE SURGICAL, INC.	+18.87%	142B
BOSTON SCIENTIFIC CORPORATION	+30.03%	111B
SIEMENS HEALTHINEERS AG	+2.17%	65.32B
EDWARDS LIFESCIENCES CORPORATION	+14.15%	52.45B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+2.68%	49.8B
AGILENT TECHNOLOGIES, INC.	+6.60%	43.43B
GE HEALTHCARE TECHNOLOGIES INC.	+1.85%	35.95B

Other Advanced Medical Equipment & Technology

Oxford Nanopore Technologies plc

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Oxford Nanopore Technologies Limited Appoint Wendy Becker as Senior Independent Director, Effective 21 January 2022

Latest news about Oxford Nanopore Technologies plc

Chart Oxford Nanopore Technologies plc

Company Profile

Income Statement Evolution

Ratings for Oxford Nanopore Technologies plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology